Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    seliciclib
Show Display Options
Rank Status Study
1 Recruiting Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Condition: Cystic Fibrosis
Interventions: Drug: Roscovitine;   Drug: Placebo
2 Withdrawn Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Seliciclib
3 Recruiting Treatment of Cushing's Disease With R-roscovitine
Condition: Cushings Disease
Intervention: Drug: R-roscovitine
4 Recruiting A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: sapacitabine and seliciclib
5 Terminated Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: seliciclib;   Drug: placebo

Indicates status has not been verified in more than two years